Home > Treatment Options > Tumor Suppressors > Clinical Trials >

GSK2256098

Last Updated: 02/2/18

Status: Currently a NF2 Clinical Trial



Chemical Structure, GSK2256098

Index

  1. Basic Information
  2. Sources
Other Names GSK-2256098; GSK 2256098
Pharmaceutical Companies GlaxoSmithKline
NF2 Trial Availability USA 2016
Taken By Pill (oral)
Tumor Target Recurrent Meningioma
NF2 Trials Recruiting Trial: NCT02523014
Inhibitor Focal Adhesion Kinase Inhibitors (FAK Kinase Inhibitors) - FAK Y397 Inhibitor
Molecular Formula C20H23ClN6O2

Source:

  1. "GSK2256098" National Center for Biotechnology Information. PubChem Compound Database; CID=46214930, https://pubchem.ncbi.nlm.nih.gov/compound/46214930
  2. Alvarez-Breckenridge, Christopher, and Priscilla K. Brastianos. "SMO mutant olfactory groove meningiomas-the next in line for targeted therapy." Neuro-Oncology 19.3 (2017): 305-306.
    Source: https://academic.oup.com/neuro-oncology/article-abstract/19/3/305/3045157 DOI: 10.1093/neuonc/now302

  3. Serrels, Alan, and Margaret C. Frame. "FAK goes nuclear to control antitumor immunity-a new target in cancer immuno-therapy." Oncoimmunology 5.4 (2016): e1119356.
    Source: (select PDF to read in full) | DOI: 10.1080/2162402X.2015.1119356

  4. Mulholland, Paul, et al. "Atnt-06 Evaluation of The Safety Of Gsk2256098 And Pharmacokinetics Of 11c-Gsk2256098 In Patients With Recurrent Glioblastoma By Positron Emission Tomography (Pet) Imaging." Neuro-oncology 17.suppl_5 (2015): v11-v11.
    Source: https://academic.oup.com/neuro-oncology/article/17/suppl_5/v11/2765358/ATNT-05INTRAOPERATIVE-INTRAPARENCHYMAL-INJECTION | DOI: 10.1093/neuonc/nov205.05

  5. Zhang, Jianliang, et al. "A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells." Cell Cycle 13.19 (2014): 3143-3149.
    Source: http://www.tandfonline.com/doi/abs/10.4161/15384101.2014.949550 | DOI: 10.4161/15384101.2014.949550

  6. Soria, Jean-Charles, et al. "A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors." Annals of Oncology 27.12 (2016): 2268-2274.
    Source: https://academic.oup.com/annonc/article-abstract/27/12/2268/2736353 | DOI: 10.1093/annonc/mdw427

  7. MDE - Med Chem Express. "GSK2256098."
    Source: http://www.medchemexpress.com/gsk2256098.html?gclid=Cj0KEQjwzYDMBRC1-JHJ7pPU278BEiQAwCv6JvSZEOZ-FIeo4gJniXqejnj7XoQ6FbgzcxBww2CoRoEaAgqH8P8HAQ

  8. "A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells." Cell Cycle. 13(19):3143-9. (2014)
    Source: https://www.ncbi.nlm.nih.gov/pubmed/25486573 | DOI: 10.4161/15384101.2014.949550.

  9. "PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer." Mol Cancer Ther. (6):1466-1475. (Released: June 2014 | Update: Apr 2015)
    Source: https://www.ncbi.nlm.nih.gov/pubmed/25833835 | DOI: doi: 10.1158/1535-7163.MCT-14-1077.
What is NF2? | About Us | Treatment Options | Sitemap

Disclaimer: Neurofibromatosis Type 2 - Information and Services, www.nf2is.org, is not run by medical experts, affiliated with any healthcare organization or any other company. No assurance can be made to the accuracy or completeness of the information provided here, the accuracy of other sites to which this site links, or of sites that link to this site. - Read More

Copyright © 2008 - 2019